Clozapine is restricted to treating schizophrenia in people who have not
responded to, or are intolerant of, other treatments, as it can cause rare, but
serious side effects. It is also used for treating psychotic illness in people
with Parkinson’s disease where other treatments have not worked.
The major classes of prescription drugs are failures. Most drugs are never
designed to address the underlying biochemical causes of disease — and they may
intentionally be designed to create life-long dependency. …
Olanzapine long-acting injection is an investigational formulation that combines
olanzapine, an atypical antipsychotic, with pamoic acid resulting in a salt that
sustains the delivery of olanzapine for a period of up to four weeks.
Long-acting injectables have been associated with improved treatment for
patients who struggle with adherence to oral medications.(i) …
Extensive clinical testing would be needed to draw conclusions about the safety
of TOFA and C75, or similar compounds, as antiviral treatment. That said, the
team took an early look at toxicity, exposing uninfected fibroblasts to C75 or
TOFA for 96 hours. They found that the drugs blocked HCMV replication without
causing cell toxicity or self-destruction (apoptosis). …
“Our new study is very promising because it suggests that we could alleviate
pain by targeting the cannabinoid receptor CB2 without causing the kinds of
side-effects we associate with people using cannabis itself.”
…
Because even the most benign of side effects has the potential of
becoming fatal in certain circumstances if left unaddressed, it is
imperative for patients, clinicians, pharmacists, and all health care
professionals to be aware of adverse reactions and possible complica
tions of clozapine therapy to prevent significant morbidity and
mortality. …
Clozapine is a substrate for many CYP450 isozymes, in particular 1A2, 2D6, and
3A4. The risk of metabolic interactions caused by an effect on an individual
isoform is therefore minimized. Nevertheless, caution should be used in patients
receiving concomitant treatment with other drugs that are either inhibitors or
inducers of these enzymes. …
some differences in drug efficacy response, and some toxicities, are based on
variability in exposure or in pharmacodynamic response, caused by genetic
differences …
The polymorphic forms of the CYP450s are responsible for the
development of a significant number of adverse drug reactions and may
also contribute to drug response. …